Screener
Icahn Enterprises IEP Pharma — Liabilities
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| Accounts payable, accrued expenses and other liabilities | $752 | $1,578 | $711 | $110 | $28 | $38 | $63 | $75 | $3,355 |
| Securities sold, not yet purchased, at fair value | 1,000 | — | — | — | — | — | — | — | 1,000 |
| Debt | — | 1,783 | 25 | 129 | 1 | 25 | — | 4,426 | 6,389 |
| Total liabilities | 1,752 | 3,361 | 736 | 239 | 29 | 63 | 63 | 4,501 | 10,744 |
| Equity attributable to Icahn Enterprises | 1,978 | 575 | 554 | 178 | 1,128 | 148 | 153 | (3,705) | 1,009 |
| Equity attributable to non-controlling interests | 593 | 533 | — | 11 | — | — | — | — | 1,137 |
| Total equity | 2,571 | 1,108 | 554 | 189 | 1,128 | 148 | 153 | (3,705) | 2,146 |
| Total liabilities and equity | $4,323 | $4,469 | $1,290 | $428 | $1,157 | $211 | $216 | $796 | $12,890 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — liabilities?
- Icahn Enterprises (IEP) reported pharma — liabilities of $63M in Q2 2026.
- How has Icahn Enterprises's pharma — liabilities changed year-over-year?
- Icahn Enterprises's pharma — liabilities increased by 12.5% year-over-year, from $56M to $63M.
- What is the long-term trend for Icahn Enterprises's pharma — liabilities?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — liabilities has grown at a 5.2% compound annual growth rate (CAGR), from $202M to $247M.
- What does pharma — liabilities mean?
- The total financial obligations and debts owed by the pharmaceutical segment to external parties. This figure encompasses both current operational payables and long-term debt or other financial commitments. It is a key measure of the segment's financial leverage and risk profile.
Ask your AI about Icahn Enterprises's pharma — liabilities.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude